July 13, 2014 4:15 AM ET

Personal Products

Company Overview of Larrea Biosciences Corporation

Company Overview

Larrea Biosciences Corporation, through its subsidiary, LarreaRx, Inc., engages in manufacturing, licensing, and distributing green dietary supplements. Its products are derived from the desert shrub, Larrea tridentate. The proprietary extract from this plant include Larreastatin, which is the key ingredient in company’s products comprising dietary supplement capsules, topical lotion, and topical spray. The company sells its products through retail channels, direct marketing channels, and distributors under LarreaRx and Shegoi trade names. It has operations in the United States and Canada. Larrea Biosciences Corporation is headquartered in Houston, Texas.

1628 Marshall

Houston, TX 77006-4122

United States

1 Employees

Phone:

832-695-0096

Fax:

832-285-1307

Key Executives for Larrea Biosciences Corporation

Chief Executive Officer and Chairman
Age: 71
Compensation as of Fiscal Year 2014.

Larrea Biosciences Corporation Key Developments

SEC Revokes Registration Of Registered Securities Of Larrea Biosciences

An Administrative Law Judge has issued an initial decision of default as to Larrea Biosciences Corporation. The Order Instituting Proceedings alleged that the company repeatedly failed to file timely periodic reports while its securities were registered with the Securities and Exchange Commission (SEC or the Commission). SEC finds these allegations to be true as to company and revokes the registration of each class of their registered securities, pursuant to Section 12(j) of the Securities Exchange Act of 1934.

SEC Orders Hearing On Registration Suspension Or Revocation Against Larrea Biosciences Corporation

In conjunction with trading suspension, the Securities and Exchange Commission (SEC) also instituted public administrative proceeding to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of Larrea Biosciences Corporation for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company is delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceeding.

Similar Private Companies By Industry

Company Name Region
Muscle Milk United States
eSalon LLC United States
Superwipes Inc. United States
Moby Wrap, Inc. United States
Carol's Daughter Holdings, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Larrea Biosciences Corporation, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.